Keywords
Colorectal Neoplasms ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

471 Search results.

Colorectal Cancer Non-Protocol Therapy NCT00303628 - Non-Protocol Therapy Colorectal Cancer NCT00303628 E5204

- 3/25/15 - 1 form, 2 itemgroups, 25 items, 1 language
Itemgroups: Header, Non-Protocol Therapy
E5204 Non-Protocol Therapy Form Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer NCT00303628 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=089B4967-A7D1-3905-E044-0003BA3F9857

Eligibility Colorectal Neoplasms NCT02487992

- 3/6/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02487992

Eligibility Colorectal Neoplasms NCT02450656

- 3/6/19 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Colorectal, Non-small Cell Lung and Pancreatic Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02450656

Eligibility Colorectal Neoplasms NCT02103062

- 3/6/19 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02103062

Eligibility Colorectal Neoplasm NCT02384850

- 3/5/19 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02384850

Eligibility Colorectal Neoplasm NCT02244632

- 3/5/19 - 1 form, 2 itemgroups, 29 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Modufolin® in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02244632

Eligibility Colorectal Carcinoma NCT02376452

- 3/5/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02376452

Eligibility Colorectal Carcinoma NCT02337946

- 3/5/19 - 1 form, 1 itemgroup, 35 items, 1 language
Itemgroup: Criteria
Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Patients With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02337946

Eligibility Colorectal Carcinoma NCT02248805

- 3/5/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02248805

Eligibility Colorectal Cancer Screening NCT02481219

- 3/3/19 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Optimization of the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure; ODM derived from: https://clinicaltrials.gov/show/NCT02481219

Eligibility Colorectal Cancer Screening NCT02419716

- 3/3/19 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval; ODM derived from: https://clinicaltrials.gov/show/NCT02419716

Eligibility Colorectal Cancer NCT02439385

- 3/3/19 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis; ODM derived from: https://clinicaltrials.gov/show/NCT02439385